episil® is a new and effective local treatment of pain associated e.g. with oral mucositis. The product is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms into a highly bioadhesive FluidCrystal® barrier film that protects the sensitised and sore mucosa of the oral cavity. episil® is conveniently administered with a convenient pump spray device that is ready for use.
mucositis is a severe side-effect of chemotherapy or radiotherapy
during cancer treatment. It is caused by damage to the DNA in the basal
epithelial cell lining of the mouth leading to decreased cell
proliferation ability which may result in ulceration and opportunistic
mouth infections. Oral mucositis is often a dose-limiting factor in the
treatment of cancer. In more severe cases, oral mucositis can be
extremely painful, preventing the patient from eating and necessitating
hospitalization for re-hydration, opiate pain medication and total
episil® is shown to give rapid and extended reduction of pain in head and neck cancer patients suffering from radiation induced oral mucositis, and is reported safe and well tolerated. Significant pain relief was maintained over at least 8 hours following single-dose administration. episil® is granted 501(k) market clearance by the US FDA and CE mark in EU. The product is currently marketed in Europe and Israel through Camurus' commercial partners, see also www.episil.net.